Internal Medicine, Hematology & Oncology · West Reading, PA
NPI
1417918244
Since 2006
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
2
Medicare group memberships
Hospitals
0
Hospital affiliations
S 6th Avenue & Spruce Street, N-Ground Trhmc Regional Cancer Center
West Reading, PA, 19611
Phone (610) 374-4404
Groups this clinician bills Medicare through
Medicare paid, 2024
$37K
384 services
Medicare patients, 2024
219
Average age 75
Drug cost, 2024
$1.8M
502 prescriptions
Company payments, 2023
$31.52
From 2 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Meide Lu was code 99215 (office e&m - established), 200 times for 97 patients. In total Meide Lu billed 384 services in 15 codes, and Medicare paid $37K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2010-03-17.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99215 Office E&M - Established | Facility | 200 | 97 | $99.95 | $20K |
| 99214 Office E&M - Established | Facility | 86 | 67 | $65.41 | $5,625 |
| 99223 Hospital E&M - Initial | Facility | 60 | 57 | $131.52 | $7,891 |
| 99233 Hospital E&M - Subsequent | Facility | 12 | 11 | $89.73 | $1,077 |
By year: 2022 $95K for 945 services; 2023 $91K for 905 services; 2024 $37K for 384 services.
Medicare prescription drug claims, 2024
In 2024, the drug Meide Lu prescribed most often to Medicare patients was Eliquis (Apixaban), with 56 prescriptions and refills. In total Meide Lu wrote 502 Medicare prescriptions that cost $1.8M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Eliquis Apixaban | 56 | 78 | 14 | $44K |
| Xarelto Rivaroxaban | 40 | 50 | Under 11 | $26K |
| Prochlorperazine Maleate Generic | 39 | 39 | 25 | $436 |
| Hydroxyurea Generic | 30 | 52 | Under 11 | $435 |
| Brukinsa Zanubrutinib | 27 | 27 | Under 11 | $353K |
| Ondansetron Hcl Generic | 24 | 24 | 16 | $225 |
| Tabrecta Capmatinib Hydrochloride | 19 | 19 | Under 11 | $420K |
| Tagrisso Osimertinib Mesylate | 19 | 19 | Under 11 | $316K |
| Dexamethasone Generic | 18 | 20 | Under 11 | $175 |
| Levothyroxine Sodium Generic | 18 | 22 | Under 11 | $96.31 |
| Lidocaine-Prilocaine Lidocaine/Prilocaine | 16 | 25 | 15 | $197 |
| Morphine Sulfate Er Morphine Sulfate | 16 | 16 | Under 11 | $365 |
| Imatinib Mesylate Generic | 15 | 15 | Under 11 | $167K |
| Ondansetron Odt Ondansetron | 14 | 14 | Under 11 | $154 |
| Acyclovir Generic | 13 | 21 | Under 11 | $154 |
Brand drugs: 197 claims; generic drugs: 305 claims; opioid claims: 42.
Money and other things of value reported by the companies
In 2023, drug and medical device companies paid Meide Lu $31.52 ($31.52 in general payments such as food, travel and fees) from 2 companies. The largest payer was Incyte Corporation with $16.2.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.